Relapsed angioimmunoblastic T-cell lymphoma with large pericardial effusion

Sawhney, Rahul; Volkmer, Randy; Cooper, Barry

doi:10.1080/08998280.2019.1668720

Cited by 4 publications

(2 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Older age (>60 years old), elevated WBC and IgA levels, thrombocytopenia, high international prognostic index and prognostic index for PTCL-U scores, and number of extranodal involvement sites >1 were adverse factors for OS [3,25,26]. Patients with AITL with polyserous effusions seem to have poor endings [27,28]. Plasma cell hyperplasia seems to have no prognostic significance in AITL patients [17].…”

Section: Discussionmentioning

confidence: 99%

The Early Diagnostic Dilemma in Angioimmunoblastic T Cell Lymphoma with Excessive Plasma Cells Proliferation

Wang

Mao

Liu

et al. 2021

Case Reports in Medicine

View full text Add to dashboard Cite

Background. Angioimmunoblastic T cell lymphoma (AITL) is an aggressive Epstein–Barr virus-associated T cell lymphoma. Clinical syndromes of AITL are not confined to fever and lymphadenopathy, and patients may initially present with polyclonal plasma cell proliferation, which may obscure the underlying disease of AITL, delaying diagnosis. Case Presentation. Here, we report two AITL patients with excessive plasma cell proliferation in the bone marrow, peripheral blood, and ascites even mimicking plasma cell leukemia. Both of them had poor endings. Conclusions. Our report emphasizes the complexity of the clinical manifestations of AITL, which aims to increase the alertness of physicians and improve the rate of early diagnosis. Integrated diagnostic approaches such as histopathology, flow cytometry, cytogenetics, and molecular biology are essential for accurate diagnosis and precise therapy.

show abstract

Section: Discussionmentioning

confidence: 99%

The Early Diagnostic Dilemma in Angioimmunoblastic T Cell Lymphoma with Excessive Plasma Cells Proliferation

Wang

Mao

Liu

et al. 2021

Case Reports in Medicine

View full text Add to dashboard Cite

show abstract

“…Lenalidomide single agent or combined with steroids could induce complete responses in patients with refractory AITL [ 87 , 88 ]. As monotherapy, ORR was 31% in 26 AITL patients of phase II EXPECT trial.…”

Section: Treatmentmentioning

confidence: 99%

Recent Advances in Diagnosis and Therapy of Angioimmunoblastic T Cell Lymphoma

et al. 2021

View full text Add to dashboard Cite

Angioimmunoblastic T cell lymphoma (AITL) is a common subtype of mature peripheral T cell lymphoma (PTCL). As per the 2016 World Health Organization classification, AITL is now considered as a subtype of nodal T cell lymphoma with follicular helper T cells. The diagnosis is challenging and requires a constellation of clinical, laboratory and histopathological findings. Significant progress in the molecular pathophysiology of AITL has been achieved in the past two decades. Characteristic genomic features have been recognized that could provide a potential platform for better diagnosis and future prognostic models. Frontline therapy for AITL was mainly depending on chemotherapy and the management of relapsed or refractory AITL is still unsatisfactory with a very poor prognosis. Upfront transplantation offers better survival. Novel agents have been introduced recently with promising outcomes. Several clinical trials of combinations using novel agents are underway. Herein, we briefly review recent advances in AITL diagnosis and the evolving treatment landscape.

show abstract